

RECEIVED

JAN 07 2002

11/2

TECH CENTER 1600/2900

Sheet 1 of 1

Form 1449*	Atty. Docket No.: 697.013US1	Serial No. 09/524,454
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Kristian Berg et al.	
	Filing Date: March 10, 2000	Group: 1644

U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
-----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
-----------------------	-----------------	------	---------	-------	----------	-----------------------

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner Initial	
<i>AE</i>	Canti, G., et al., "Antitumor immunity induced by photodynamic therapy with aluminum disulfonated phthalocyanines", <u>Anti-Cancer Drugs</u> , Vol. 5, pp. 443-447, (1994) ✓
	de Vree, W.J., et al., "Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo", <u>Cancer Research</u> , Vol. 56, pp. 2908-2911, (July 1, 1996) ✓
	Korbelik, M., et al., "Photodynamic therapy-mediated immune response against subcutaneous mouse tumors", <u>Cancer Research</u> , Vol. 59, pp. 1941-1946, (April 15, 1999) ✓
	Lee, S., et al., "Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials", <u>Journal of Immunotherapy</u> , Vol. 23, No. 3, pp. 379-386, (2000) ✓
	Philip, R., et al., "Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma", <u>Journal of Immunotherapy</u> , Vol. 23, No. 1, pp. 168-176, (2000) ✓
<i>AE</i>	Wang, F., et al., "Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma", <u>Clinical Cancer Research</u> , Vol. 5, pp. 2756-2765, (October 1999) ✓

Examiner

Fuchs

Date Considered

6/6/02

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.